, podcast host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, and Yan Leyfman, MD, a resident physician at Mount Sinai in New York, New York, discussed the origins and mission of 

, a global platform designed to combat health care misinformation and advance medical education. Conceived during the COVID-19 pandemic, 

 was created in response to widespread misinformation and a need for accessible, evidence-based information. Over the past 2 and a half years, the platform has expanded to reach over 100 countries, focusing on underserved regions and amplifying the voices of both established oncology leaders and early-career researchers.

The platform offers educational initiatives like Keynote Conference, a 1-hour session featuring expert presentations and interactive Q&A sessions; and Medical Spotlight, which highlights the professional journeys and research of global experts. 

 provides a real-world perspective on how oncologists incorporate trial data into clinical practice, addressing patient-specific considerations often missed in formal conferences. In this episode, Dr Park emphasized 

’s commitment to mentorship, providing trainees with opportunities to publish research, present at conferences, and secure residency placements, particularly those in resource-limited settings.

 to amplify its global reach, leveraging 

’s expansive platform to deliver concise, interactive, and accessible oncology education tailored to modern audiences. By emphasizing equity and inclusion, this initiative aims to address disparities in professional opportunities and foster a more diverse and innovative oncology community. In this discussion, Drs Park and Leyfman reaffirmed their commitment to advancing global medical education, mentoring future leaders, and bridging gaps in access to accurate health care information.

Podcasts

Drs Park and Leyfman discuss their commitment to advancing global medical education, mentoring future leaders, and bridging gaps in access to accurate health care information.

MedNews Week Advances Global Oncology Education and Combats Misinformation: With Chandler Park, MD; and Yan Leyfman, MD

Dr Raje on the DREAMM-7 and DREAMM-8 Trials in Multiple Myeloma

Noopur S. Raje, MD, director, Center for Multiple Myeloma, Massachusetts General Hospital, Mass General Brigham, and Yan Leyfman, MD, internal medicine and clinical researcher, Mount Sinai; co-founder, executive director, MedNews Week; executive committee member, Music Beats Cancer, discuss the phase 3 DREAMM-7 (NCT04246047) and DREAMM-8 (NCT04484623) trials on 

Belantamab mafodotin-blmf (Blenrep) has experienced a turbulent journey in multiple myeloma, Raje begins. Initially, this agent was withdrawn from the United States market; however, at the 2024 ASCO Annual Meeting, significant new data were presented that shed light on its potential efficacy, she explains. In addition to 

Belantamab mafodotin is an antibody-drug conjugate (ADC) targeting BCMA, she continues. This drug is noteworthy as it represents the first ADC developed for this purpose, Raje says. DREAMM-7 explores the use of belantamab mafodotin in combination with bortezomib (Velcade) and dexamethasone (BVd) compared with the combination of daratumumab (Darzalex), bortezomib, and dexamethasone (DVd) in patients with relapsed/refractory multiple myeloma. The results from DREAMM-7 are promising, showing a benefit in progression-free survival (PFS) with BVd vs DVd and indicating a trend toward improved overall survival with BVd, she elucidates.

The DREAMM-8 study examined belantamab mafodotin combined with pomalidomide (Pomalyst) and dexamethasone compared with the triplet combination of pomalidomide, bortezomib, and dexamethasone. This study also demonstrated an improvement in PFS with the belantamab mafodotin–based regimen, Raje explains.

DREAMM-7 and DREAMM-8 are poised to play a crucial role in reintroducing belantamab mafodotin into the multiple myeloma treatment paradigm, she continues. Both studies showed efficacy with the agent in the relapsed/refractory setting. The data presented at ASCO in 2024 will be critical in determining the future role of belantamab mafodotin in myeloma and could mark a significant step forward in the treatment of patients with this disease, particularly those who have relapsed on or are refractory to existing treatments, Raje concludes.

Videos

Noopur S. Raje, MD, and Yan Leyfman, MD, discuss the phase 3 DREAMM-7 and DREAMM-8 trials on OncLive News Network: On Location.

Dr Levy on the Clinical Application of ADCs in NSCLC Following ASCO 2024 Data

Benjamin Levy, MD, clinical director, Medical Oncology, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospital; associate professor, oncology, Johns Hopkins University School of Medicine, and Yan Leyfman, MD, internal medicine and clinical researcher, Mount Sinai; co-founder, executive director, MedNews Week, executive committee member, Music Beats Cancer, discuss the clinical application of antibody-drug conjugates (ADCs) in the treatment of patients with non–small cell lung cancer (NSCLC) on 

When asked which ADCs show the most promising potential for clinical applications, Levy states that the 2024 ASCO Annual Meeting appears to be the first ASCO Annual Meeting with so many ADC presentations, reflecting rapid advancements in the field. There are multiple promising options, with findings from the phase 3 EVOKE-01 trial (NCT05089734) taking a prominent place, he says. This study compares sacituzumab govitecan-hziy (Trodelvy) with docetaxel in the second-line setting in an enriched patient population that includes patients with both nonsquamous and squamous disease. Unfortunately, the study 

 of overall survival, but findings from subset analyses will be informative, Levy reports.

The phase 2 TROPION-Lung05 trial (NCT04484142)

 examined intracranial response rates with single-agent datopotamab deruxtecan (Dato-DXd), a TROP2-directed ADC, in patients with actionable genomic alterations, Levy continues, adding that the study showed an intracranial overall response rate of 22% (95% CI, 6%-48%) in patients with baseline brain metastases, indicating that ADCs can cross the blood-brain barrier.

Another ADC of interest is telisotuzumab vedotin, a MET-directed ADC. Data from the phase 2 LUMINOSITY/M14-239 trial (NCT03539536) were discussed at the meeting, focusing on both patients with 

-mutant NSCLC. Preliminary results indicate that patients with wild-type disease with high 

 expression derive the most benefit. The nuances of these data will be intriguing to explore, Levy says.

The 2024 ASCO Annual Meeting was incredibly exciting with so much progress seen in the ADC field, especially as advancements in TROP2-directed ADCs, MET-directed ADCs, and translational and predictive biomarkers propel the field forward, according to Levy. This is a thrilling time to witness these developments, he concludes.

Benjamin Levy, MD, and Yan Leyfman, MD, discuss the clinical application of antibody-drug conjugates in non–small cell lung cancer.

Reviewing the Latest in Breast Cancer and Myeloma

Breast Cancer and Multiple Myeloma Advances

OncLive® will be LIVE with OncLive® News Network: On Location at the 2024 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference

Reviewing the Latest in Breast Cancer and Myeloma: Drs Tarantino and Raje

Dr Ben Levy and Dr Saint Fleur Discuss ASCO 2024 Data

Dr Levy and Dr Saint Fleur: On Location

OncLive® will be LIVE with OncLive® News Network: On Location at the 2024 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Yan Leyfman, MD

Articles

MedNews Week Advances Global Oncology Education and Combats Misinformation: With Chandler Park, MD; and Yan Leyfman, MD

Dr Raje on the DREAMM-7 and DREAMM-8 Trials in Multiple Myeloma

Dr Levy on the Clinical Application of ADCs in NSCLC Following ASCO 2024 Data

Reviewing the Latest in Breast Cancer and Myeloma: Drs Tarantino and Raje

Sifting Through Data in Lung Cancer and Leukemia: Drs Levy and Saint Fleur